Yep. Given that expectations seem to be low for ASCO, it may set the stage for an upside surprise in price if they actually deliver more data (like number of patients still alive) than we expect.
Hope I didn’t just jinx anything! ;-)
In any case, I’m not interested in short-term jumps in price. It’s all about the final trial results in the end.
News 
Market Data 
Discover 
